, its genetically engineered bacterium in preparing drugs for the treatment of prostate cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 13, 2016
Grant Date -
N/A
app pub date -
Jul 30, 2015
filing date -
Jul 30, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The current invention discloses an attenuated Salmonella typhimurium, a genetically engineered bacterium and applications thereof in preparing drugs for the treatment of prostate cancer. The attenuated Salmonella typhimurium has tumor targeting and significant inhibitory effects on prostate cancer cells. A genetically engineered bacterium bearing a L-methioninase gene plasmid also has tumor targeting ability. The attenuated Salmonella typhimurium with the plasmid can constitutively express L-methioninase in the tumor tissues, consume a significant amount of methionine and other nutrients, which in turn causes lack of nutrition and slow growth of tumor cells. Therefore, it can be used as drugs for treating prostate cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully